表紙
市場調査レポート

世界のRNAi市場

Global RNAi Market Analysis

発行 RNCOS E-Services Pvt. Ltd. 商品コード 235803
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
世界のRNAi市場 Global RNAi Market Analysis
出版日: 2012年04月01日 ページ情報: 英文 105 Pages
概要

RNA干渉(RNAi)は、創薬、薬剤開発、治療アプリケーション、基礎研究の補助といった様々な領域で多大な潜在性を示しています。世界におけるRNA干渉市場は、2011年から2015年にかけて、CAGR17%前後で拡大する見通しです。

当レポートでは、世界のRNAi市場について広範囲な情報と分析を提供しており、RNAiのアプリケーション、技術、業界動向や競合情勢などの情報を、概略以下の構成でお届けします。

第1章 アナリストの見解

第2章 調査手法

第3章 RNAi:イントロダクション

第4章 産業概要

  • 最近の産業活動
    • 米国
    • 欧州
    • アジア太平洋地域

第5章 RNAiのアプリケーション

  • 治療
  • 創薬および薬剤開発
  • 農業

第6章 治療セグメント別のRNAi技術

  • 腫瘍
  • 眼疾患および網膜疾患
  • ウイルス感染
  • 心血管疾患
  • 神経疾患および行動欠陥
  • メタボリックシンドローム(代謝症候群)

第7章 製品およびツール別のRNAi技術

  • RNAi製品
    • RNAi阻害剤
    • RNAiライブラリー
    • RNAi試薬
    • RNAiベクター
    • RNAiアッセイ
    • RNAiコントロール
    • RNAi模倣体
  • RNAiサービス

第8章 RNAi技術 - パイプライン分析

第9章 最近の業界動向

  • ハイスループット標的検出および標的確認の研究
  • 共同開発のための戦略的活動
  • RNAiの全身デリバリーへの注力
  • 治療:最も有望なRNAiのアプリケーション

第10章 競合情勢

  • Alnylam Pharmaceuticals
  • Benitec Biopharma Ltd.
  • Bioneer Corporation
  • Calando Pharmaceuticals
  • Dharmacon
  • Galena Pharmaceuticals (RXi)
  • Integrated DNA Technologies
  • Isis Pharmaceuticals
  • Life Technologies
  • Merck (Sirna)
  • Qiagen
  • Quark Pharmaceuticals Inc
  • Sigma Aldrich Corporation
  • Silence Therapeutics
  • Tekmira Pharmaceuticals

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents an extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for various indications, and aids in the basic research. Our latest research found that various components, such as siRNA & miRNA possess immense opportunities and provide a wide range in different drug classes. These molecules also find wide applications in sectors, such as functional genomics, disease diagnostics, and agriculture, among others. It is anticipated that the global RNAi market will grow stupendously at a CAGR of around 17% during 2011-2015.

According to our new research report, "Global RNAi Market Analysis", the incessant growth of the industry will be mainly driven by the rising utilization of the RNAi as a research gizmo in functional genomics, which is used in drug discovery, target validation and drug development along with agricultural & plant biotechnology sectors. RNAi-based therapeutics are one the most lucrative segments, and our report elaborates various applications of RNAi technologies and molecules in the ongoing research and discovery of disease applications, such as oncology, ocular retinal disorders, viral infections and cardiac diseases, among others.

Our report identified that RNAi technologies will have a highly promising outlook as there are several products in the pipeline. Within the sector, therapeutic pipeline products possess a significant potential, which is yet to be tapped. The usage of siRNA and miRNA in industries and academic institutions will witness a substantial growth with the passage of time. Based on exhaustive research, the report identifies some of the key companies present in the RNAi industry, ranging from research-oriented firms to RNAi dedicated products and service providers. We have also enlisted some of the key RNAi products and services having diversely profound applications.

Our report also looks into the key market trends and recent developments across various geographies. The thoroughly examined market applications, industrial developments, and competitive landscape will help clients understand the market structure and its progress in the coming years. Through this comprehensive report, companies planning to venture into the RNAi sector will have an in-depth understanding of the market dynamics.

Table of Contents

1. Analyst View

2. Research Methodology

3. RNAi - An Introduction

4. Industry Overview

  • 4.1 Recent Industry Activities
    • 4.1.1 US
    • 4.1.2 Europe
    • 4.1.3 Asia Pacific

5. RNAi Applications

  • 5.1 Therapeutics
  • 5.2 Drug Discovery & Development
  • 5.3 Agriculture

6. RNAi Technologies by Therapeutic Segment

  • 6.1 Oncology
  • 6.2 Ocular and Retinal Disorders
  • 6.3 Viral Infections
  • 6.4 Cardiac Diseases
  • 6.5 Neuronal and Behavioral Disorders
  • 6.6 Metabolic Syndrome

7. RNAi Technologies by Products and Tools

  • 7.1 RNAi Products
    • 7.1.1 RNAi Inhibitors
    • 7.1.2 RNAi Libraries
    • 7.1.3 RNAi Reagents
    • 7.1.4 RNAi Vectors
    • 7.1.5 RNAi Assays
    • 7.1.6 RNAi Controls
    • 7.1.7 RNAi Mimics
  • 7.2 RNAi Services

8. RNAi Technologies - Pipeline Analysis

9. Recent Industry Trends

  • 9.1 Research Focused on High-Throughput Target Discovery and Target Validation
  • 9.2 Strategic Activity Progressing for Consolidated Developments
  • 9.3 Companies Focusing on Systemic Delivery for RNAi
  • 9.4 Therapeutics: Most Promising Application for RNAi

10. Competitive Landscape

  • 10.1 Alnylam Pharmaceuticals
  • 10.2 Benitec Biopharma Ltd.
  • 10.3 Bioneer Corporation
  • 10.4 Calando Pharmaceuticals
  • 10.5 Dharmacon
  • 10.6 Galena Pharmaceuticals (RXi)
  • 10.7 Integrated DNA Technologies
  • 10.8 Isis Pharmaceuticals
  • 10.9 Life Technologies
  • 10.10 Merck (Sirna)
  • 10.11 Qiagen
  • 10.12 Quark Pharmaceuticals Inc
  • 10.13 Sigma Aldrich Corporation
  • 10.14 Silence Therapeutics
  • 10.15 Tekmira Pharmaceuticals

List of Figures:

  • Figure 3-1: Process of Viral Replication
  • Figure 3-2: RNAi Action Mechanism
  • Figure 3-3: Processing of dsRNA & shRNA
  • Figure 4-1: Global - RNAi Market (Billion US$), 2011 & 2015

List of Tables:

  • Table 5-1: Advantages of RNAi Therapies over Conventional Drugs
  • Table 6-1: Pipeline RNAi Drugs for Oncology
  • Table 6-2: Pipeline RNAi Drugs for Ocular and Retinal Disorders
  • Table 6-3: Prevalence Statistics of Viral Infections
  • Table 6-4: Pipeline RNAi Drugs for Viral Infections
  • Table 7-1: RNAi Inhibitors Products of Key Companies
  • Table 7-2: RNAi Library Products of Key Companies
  • Table 7-3: RNAi Reagent Products of Key Companies
  • Table 7-4: RNAi Vector Products of Key Companies
  • Table 7-5: RNAi Assays Products of Key Companies
  • Table 7-6: RNAi Control Products of Key Companies
  • Table 7-7: RNAi Mimic Products of Key Companies
  • Table 7-8: RNAi Services of Key Companies
  • Table 8-1: Pipeline RNAi Drugs of Key Companies by Phase
  • Table 10-1: Alnylam - Key RNAi Products in Pipeline
  • Table 10-2: Benitec - Key RNAi Products in Pipeline
  • Table 10-3: Bioneer Corporation - Key RNai Products
  • Table 10-4: Calando Pharmaceuticals - Key RNAi Products in Pipeline
  • Table 10-5: Dharmacon - Key RNAi Products
  • Table 10-6: Galena Pharmaceuticals (RXi) - Key RNAi Products in Pipeline
  • Table 10-7: Integrated DNA Technologies - Key RNAi Products
  • Table 10-8: Life Technologies Corporation - Key RNAi Products
  • Table 10-9: Qiagen - Key RNAi Products
  • Table 10-10: Quark Pharmaceuticals - Key RNAi Products in Pipeline
  • Table 10-11: Sigma-Aldrich Corporation - Key RNAi Products
  • Table 10-12: Silence Therapeutics - Key RNAi Products
  • Table 10-13: Silence Therapeutics - Key RNAi Products in Pipeline
  • Table 10-14: Tekmira Pharmaceuticals - Key RNAi Products in Pipeline
Back to Top